Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight [Yahoo! Finance]
Climb Bio, Inc. (CLYM)
Company Research
Source: Yahoo! Finance
prevalence, enhanced diagnostic capabilities, and increased adoption of supportive and emerging targeted therapies such as SNP-ACTH (1-39) Gel (Cerium Pharmaceuticals), BRUKINSA (zanubrutinib) (BeiGene), GAZYVA (obinutuzumab) (Hoffmann-La Roche), MOR202 (felzartamab) (Biogen), Budoprutug (Climb Bio), and others. New York, USA, April 06, 2026 (GLOBE NEWSWIRE) Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight The idiopathic membranous nephropathy market is poised for steady expansion driven by rising disease prevalence, enhanced diagnostic capabilities, and increased adoption of supportive and emerging targeted therapies such as SNP-ACTH (1-39) Gel (Cerium Pharmaceuticals), BRUKINSA (zanubrutinib) (BeiGene), GAZYVA (obinutuzumab) (Hoffmann-La Roche), MOR202 (felzartamab) (Biogen), Budoprutug (Climb Bio), and others. Recently published Idiopathic Membranous Nephropathy Market Insights report include
Show less
Read more
Impact Snapshot
Event Time:
CLYM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLYM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLYM alerts
High impacting Climb Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CLYM
News
- Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway [Seeking Alpha]Seeking Alpha
- Climb Bio (CLYM) was upgraded by Mizuho to "strong-buy".MarketBeat
- Climb Bio (CLYM) was given a new $18.00 price target by Mizuho.MarketBeat
- Climb Bio (CLYM) had its "buy" rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.MarketBeat
- Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026GlobeNewswire
CLYM
Sec Filings
- 4/10/26 - Form PRE
- 4/3/26 - Form 8-K
- 3/5/26 - Form S-8
- CLYM's page on the SEC website